We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers integrates AI, telemedicine and cloud pharmacy for personalized chronic care delivery.
HIMS' Mo Elshenawy to lead AI-driven diagnostics and raised $870 million via convertible notes to fund growth.
HIMS expands AI care with digital testosterone therapy and Hers Menopause personalization tools.
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , is redefining healthcare delivery through a vertically integrated, technology-driven model that merges telemedicine, data infrastructure and AI-enabled personalization. The company’s proprietary platform connects patients to licensed providers through digital consultations, electronic medical records and cloud-based pharmacy fulfillment, enabling personalized treatment for chronic conditions ranging from mental health to dermatology and weight loss. This digital ecosystem facilitates end-to-end care — from virtual intake to diagnosis and fulfillment — while maintaining clinical quality through algorithmic follow-up and evidence-based protocols.
In May 2025, Hims & Hers deepened its AI investment with the appointment of Mo Elshenawy to lead the development of advanced healthcare algorithms and diagnostic tools designed to connect diagnosis, treatment and delivery seamlessly across its global network. HIMS’ $870 million convertible notes offering further supports the expansion of AI and personalized treatment pipelines.
Recent product innovations reflect this strategy in action. The exclusive oral testosterone launch for men introduces a digitally managed hormone therapy program powered by data and provider insights, while the Hers Menopause and Perimenopause specialty leverages AI-guided care personalization to address complex hormonal health needs at scale. Together with global expansion via the ZAVA acquisition, these initiatives position Hims & Hers as a leader in AI-driven, consumer-centric healthcare designed for accessibility, precision and scalability.
TEM & TDOC’s AI-Driven Precision and Virtual Care Platforms
Tempus AI, Inc. (TEM - Free Report) drives technology-based healthcare through its Intelligent Diagnostics platform, which applies AI to integrate genomic, clinical and imaging data for individualized care. Tempus connects over 3,000 healthcare institutions via a multimodal data network, providing real-time insights that enhance diagnostics and treatment selection. In 2025, Tempus gained FDA clearances for its xR RNA sequencing and Pixel AI imaging devices and partnered with ARPA-H to advance precision oncology — solidifying its role as a leader in AI-powered precision medicine.
Teladoc Health, Inc. (TDOC - Free Report) advances technology-driven care through its AI-enabled Clarity monitoring platform and virtual health ecosystem. In 2025, Teladoc Health expanded Clarity to include AI-based workplace safety tools that analyze video and audio data to detect aggression and alert care teams. By combining predictive analytics, connected devices and telehealth, Teladoc Health delivers proactive, data-informed care that enhances patient outcomes and operational safety across hospitals and health systems.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 159.6% year to date, outperforming the industry’s growth of 30.4%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 5.3X is lower than the industry’s average of 5.9X, but is higher than its three-year median of 2.5X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 122.2% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #4 (Sell).
Image: Bigstock
Hims & Hers Elevates Technology-Driven Healthcare Accessibility
Key Takeaways
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , is redefining healthcare delivery through a vertically integrated, technology-driven model that merges telemedicine, data infrastructure and AI-enabled personalization. The company’s proprietary platform connects patients to licensed providers through digital consultations, electronic medical records and cloud-based pharmacy fulfillment, enabling personalized treatment for chronic conditions ranging from mental health to dermatology and weight loss. This digital ecosystem facilitates end-to-end care — from virtual intake to diagnosis and fulfillment — while maintaining clinical quality through algorithmic follow-up and evidence-based protocols.
In May 2025, Hims & Hers deepened its AI investment with the appointment of Mo Elshenawy to lead the development of advanced healthcare algorithms and diagnostic tools designed to connect diagnosis, treatment and delivery seamlessly across its global network. HIMS’ $870 million convertible notes offering further supports the expansion of AI and personalized treatment pipelines.
Recent product innovations reflect this strategy in action. The exclusive oral testosterone launch for men introduces a digitally managed hormone therapy program powered by data and provider insights, while the Hers Menopause and Perimenopause specialty leverages AI-guided care personalization to address complex hormonal health needs at scale. Together with global expansion via the ZAVA acquisition, these initiatives position Hims & Hers as a leader in AI-driven, consumer-centric healthcare designed for accessibility, precision and scalability.
TEM & TDOC’s AI-Driven Precision and Virtual Care Platforms
Tempus AI, Inc. (TEM - Free Report) drives technology-based healthcare through its Intelligent Diagnostics platform, which applies AI to integrate genomic, clinical and imaging data for individualized care. Tempus connects over 3,000 healthcare institutions via a multimodal data network, providing real-time insights that enhance diagnostics and treatment selection. In 2025, Tempus gained FDA clearances for its xR RNA sequencing and Pixel AI imaging devices and partnered with ARPA-H to advance precision oncology — solidifying its role as a leader in AI-powered precision medicine.
Teladoc Health, Inc. (TDOC - Free Report) advances technology-driven care through its AI-enabled Clarity monitoring platform and virtual health ecosystem. In 2025, Teladoc Health expanded Clarity to include AI-based workplace safety tools that analyze video and audio data to detect aggression and alert care teams. By combining predictive analytics, connected devices and telehealth, Teladoc Health delivers proactive, data-informed care that enhances patient outcomes and operational safety across hospitals and health systems.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 159.6% year to date, outperforming the industry’s growth of 30.4%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 5.3X is lower than the industry’s average of 5.9X, but is higher than its three-year median of 2.5X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 122.2% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.